125 related articles for article (PubMed ID: 38835325)
21. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
[TBL] [Abstract][Full Text] [Related]
22. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
Harno-Tasihin J; Siregar L; Paajanen M; Arkkila P; Punkkinen J
Scand J Gastroenterol; 2024 Mar; 59(3):280-287. PubMed ID: 38006219
[TBL] [Abstract][Full Text] [Related]
23. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
Buer LC; Moum BA; Cvancarova M; Warren DJ; Medhus AW; Høivik ML
J Crohns Colitis; 2017 Mar; 11(3):297-304. PubMed ID: 27660339
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation].
Knyazev OV; Shkurko TV; Kagramanova AV; Lishchinskaya AA; Zvyaglova MY; Korneeva IA; Babayan AF; Parfenov AI
Ter Arkh; 2019 Aug; 91(8):41-46. PubMed ID: 32598753
[TBL] [Abstract][Full Text] [Related]
25. The effect of infliximab on patients with ulcerative colitis in Korea.
Seo HI; Park DI; Kim TO; Kim YS; Lee SH; Kim JW; Kim JH; Shin JE
Intest Res; 2014 Jul; 12(3):214-20. PubMed ID: 25349595
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
[TBL] [Abstract][Full Text] [Related]
27. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
[TBL] [Abstract][Full Text] [Related]
28. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
29. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
30. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
31. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.
Ribaldone DG; Parisio L; Variola A; Bossa F; Castiglione F; Marzo M; Piazza N; Aratari A; Savarino EV; Bodini G; Mastronardi M; Micheli F; Mazzuoli S; Ascolani M; Viganò C; Cappello M; Bezzio C; Ciccocioppo R; Scardino G; Sarli E; Pugliese D; Scaldaferri F; Napolitano D; Todeschini A; Geccherle A; Colaci N; Guerra M; Annese M; Testa A; Caiazzo A; Conforti FS; Festa S; Lorenzon G; Marra A; Magiotta A; Baccini F; Amato A; Poshnjari A; Vernero M; Caprioli F; Caviglia GP;
Dig Liver Dis; 2024 Jan; 56(1):77-82. PubMed ID: 37474412
[TBL] [Abstract][Full Text] [Related]
32. Cannabis for the treatment of ulcerative colitis.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
[TBL] [Abstract][Full Text] [Related]
33. Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.
Argüelles-Arias F; Valdés Delgado T; Maldonado Pérez B; González Antuña J; Castro Laria L
Therap Adv Gastroenterol; 2023; 16():17562848231191670. PubMed ID: 37655058
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.
Guerra Veloz MF; Belvis Jiménez M; Valdes Delgado T; Castro Laria L; Maldonado Pérez B; Perea Amarillo R; Merino Bohórquez V; Caunedo Álvarez Á; Vilches Arenas Á; Argüelles-Arias F
Therap Adv Gastroenterol; 2019; 12():1756284819858052. PubMed ID: 31258621
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
[No Abstract] [Full Text] [Related]
36. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
Roblin X; Nancey S; Papamichael K; Duru G; Flamand M; Kwiatek S; Cheifetz A; Fabien N; Barrau M; Paul S
J Crohns Colitis; 2024 May; 18(5):679-685. PubMed ID: 37934041
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
Kobayashi T; Ito H; Ashida T; Yokoyama T; Nagahori M; Inaba T; Shikamura M; Yamaguchi T; Hori T; Pinton P; Watanabe M; Hibi T
Intest Res; 2021 Oct; 19(4):448-460. PubMed ID: 32806876
[TBL] [Abstract][Full Text] [Related]
38. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
[TBL] [Abstract][Full Text] [Related]
39. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
Guerra Veloz MF; Vázquez Morón JM; Belvis Jiménez M; Pallarés Manrique H; Valdés Delgado T; Castro Laria L; Maldonado Pérez B; Benítez Roldán A; Perea Amarillo R; Merino V; Caunedo Álvarez Á; Argüelles Arias F
Rev Esp Enferm Dig; 2018 Sep; 110(9):564-570. PubMed ID: 29893581
[TBL] [Abstract][Full Text] [Related]
40. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
